A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This single arm study will evaluate the efficacy and safety of MabThera monotherapy in
patients with refractory, relapsing or chronic idiopathic thrombocytopenic purpura (ITP).
Patients will receive infusions of MabThera 1000mg i.v. on days 1 and 15. The anticipated
time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.